Description
Areas of Expertise Principal CSP Program Manager MCM countermeasures Emerging CB Threats World Class Medical Consortium Biotech Business Matrix CEO, CFO Stem Cell Research Clinical Research De Novo Neuro treatments cGMP cGCP Intellectual Property Technology Transfer Global Development Northern Africa Iraq/Afghanistan The Balkans Far East 2007 - 2013 60 hrs per week $125,000 per year salary US Army USACAPOC- Served as dynamic Strategic, Corporate Chemical Engagement Surety Program (CSP) Senior Advisor. Duties: Principal CBRN, Inter-Agency Embedded Provisional Reconstruction Team Leader (ePRTs) assigned to missions in 19 countries, Near Eastern Affairs. Senior staff CBRN threat analyst. DOS ePRT Certified. Coordinates CSP intelligence analysis emphasizing Nuclear Non Proliferation for briefs to CEO, US cabinet level officials, State Department Foreign Service Officers, USAID Deputies and NGOs. Secret, Interim * Selected by Regional Iraq Ambassador Extraordinary and Plenipotentiary as ePR Team Leader, South Diyala * Effective communicator facilitated coordination of diverse Inter-Agency security forces domain for counter-terrorism efforts * Improved Strategic CBRN and CS Program efficacy rating from 3% to 97% * Granular understanding of policies, directives and Inter-Agency decision making processes 2001 - 2004 60 hrs per week $111,000 per year salary US Air Force OTEC- Principal Research Scientist, Senior Test and Evaluation Program Team Leader of 22 highly successful senior consultants and contractors. Strategic Program Leader of cutting edge technologies, Chemical Surety and Medical Counter-Measures Development (MCM). Ensured timely, accurate deliverables of urgent and operational requirements in support of global JPEO OIF and OEF CSP missions. Rapid response for Operational testing and fielding of 30+ Joint Forces Acquisitions Chemical and Biological systems. Proven good business practices resulted in acquisition of projects in excess of $1.7 billion. * Leading Co-author of Coalition, Inter-Agency CB Defense Policies and doctrines * Enterprising proposals leading to contracts. TEMPS and ORDs, DoD 5000 series Directives, Science & Technology Policies expertise * Awarded bonus for innovative engineering efforts and rapid fielding of ARTIMES CB system 2004 - 2012 30 hrs per week Student Intern Georgetown University Medical Center - Assistant to Director, Protein Assay and Protocol Design Development, Pre-Clinical Sciences. Applied, research, development and design of protein extraction assays and reagents for bio-processes in living organisms. Designs protocols for applications of bioengineering, diagnostics, biotechnology, medicine and medical devices. Chief Photometric Analyst targeting programmed cell death in neurodegenerative diseases. Prepares comprehensive technical notebooks covering summaries and quantitative analyses. Innovative designs lead to 95% efficacy laboratory protocol rating 98% pass rate of Graduate medical school students. Exceeds best practice standards of defined biotechnology. Expert in all phases of Clinical trials and Intellectual Property relative *CFRs. World Class Medical Consortium, Small Cap Biotech Business Matrixes: * CEO/COO of Innovative Mammalian Tissue Engineered STEM Cell skin scaffolding techniques * Team CFO and COO of University Medical Center Research, Phase IV, Papillomavirus vaccine. 21+ years 60 hrs per week $100,000 per year US Army - Global Strategic and Tactical Chemical, Biological, Radiological and Nuclear Program (CBDP) Officer, Army Medical Department, Joint Program Executive Office Enables the Warfighter to deter, prevent, protect, mitigate, respond, and recover from chemical, biological, radiological, and nuclear (CBRN) threats and effects as part of a layered integrated defense multiplier. Directed focus on four enduring Strategic Enterprising Domains: * Medical Countermeasure (MCM) Development protecting forces against disease in theaters of operation and against weaponized CB threats. * Diagnostics. CBR detectors and diagnostics to protect the Warfighter by quickly and effectively identifying, characterizing, and diagnosing pathogens and diseases to prepare timely and appropriate treatment. * Biosurveillance. Biosurveillance capability that will mitigate the threat from CBR events (intentional, accidental, or naturally occurring) by real time information to leadership with essential information to support decision making via technical architecture made up of disease surveillance tools, to include fielding capable diagnostic, detection, and information management and analytics technologies. * Non-Traditional Agent (NTA) Defense Capabilities. Evolving investments in NTA defense capabilities in support of the Warfighter under National NTA Defense Research, Development, Test and Evaluation (RDT&E) Strategy. Enhances capabilities to mitigate threat from non-traditional and emerging chemical threats. Directive developing NTA defense in priority areas of detection: MCMs, decontamination, and protection.
Accomplishments
Highlights:
Keywords
